The case against medical marijuana rests on several concrete problems: it bypasses the safety testing required of every other medication, its products are inconsistent and sometimes contaminated, and its use carries measurable risks to mental health, heart health, and public safety. Whether these concerns outweigh the documented benefits is a genuine policy debate, but the arguments for keeping medical marijuana illegal (or at least heavily restricted) are grounded in real data worth understanding.
It Skips Standard Drug Approval
Every prescription medication in the United States must pass through a rigorous approval process. Manufacturers must demonstrate a drug’s identity, quality, purity, and potency at each phase of clinical testing. They must document impurity profiles, metabolic behavior, and appropriate dosing. The FDA holds cannabis-derived products to these same standards on paper, but state medical marijuana programs effectively sidestep the process entirely. Patients receive whole-plant products that have never completed the multi-phase clinical trials required of any other medicine.
This matters because the approval process exists to answer basic questions: Does this drug actually work for the condition it claims to treat? What are the side effects at specific doses? How does it interact with other medications? For most conditions that medical marijuana is recommended for, these questions remain only partially answered. The one FDA-approved cannabis-derived medication on the market went through years of controlled trials before reaching patients. Dispensary products did not.
Dosing Is Unreliable
Clinical trials studying cannabis for pain relief consistently use THC concentrations below 10%, and several studies found that concentrations as low as 1 to 3% provided meaningful pain relief. Yet the products sold in dispensaries bear little resemblance to what the science supports. A study of U.S. cannabis markets found that product offerings do not reflect the evidence on what concentrations of THC and CBD could actually be therapeutic. About 58.5% of products didn’t even list CBD content, leaving patients guessing.
The result is a pharmacological mismatch. As THC potency rises, so do intoxication and the frequency of adverse events. Patients trying to manage pain end up navigating a difficult balancing act between therapeutic effects and getting uncomfortably high. Many products marketed for medical use are, in pharmacological terms, potentially harmful because their potency far exceeds what clinical evidence supports.
Contamination in Dispensary Products
State-by-state regulation creates a patchwork of testing standards that leaves gaps in product safety. An analysis of over 9,400 cannabis samples from a licensed testing lab in the Los Angeles area found pesticides, heavy metals, and microbial contaminants across both flower and concentrate products. The failure rate was 2.3% for flower and 9.2% for extracts.
The most common contaminants were insecticides and fungicides, with chlorpyrifos (a neurotoxic insecticide banned from food crops) detected in the highest number of flower samples. Extract products fared worse, containing 61 of the 103 regulated contaminants in California. Residual solvents like chloroform and benzene also turned up. On the microbial side, Aspergillus fumigatus, a fungus particularly dangerous to people with weakened immune systems (exactly the kind of patients who often seek medical marijuana), appeared in samples. At least 8 out of 14 documented recall incidents involved microbial contamination, and two involved cadmium, a toxic heavy metal.
Mental Health Risks
The link between heavy cannabis use and psychotic disorders is one of the strongest arguments against broad access. Evidence shows a dose-response relationship: more frequent use of higher-potency products correlates with greater risk of developing schizophrenia. A study published in JAMA Network Open found that people with cannabis use disorder had roughly three times the risk of being diagnosed with schizophrenia compared to non-users, with an adjusted hazard ratio of 3.07.
This is especially concerning because medical marijuana programs often authorize daily use over long periods, and the products available today are far more potent than what existed even a decade ago. For patients with a family history of psychotic disorders or those in the age window of highest vulnerability (late teens through mid-twenties), the risk profile of daily high-potency cannabis is significant.
Addiction Potential
Cannabis is often described as non-addictive, but clinical data tells a different story. A study in JAMA Network Open found that 21.3% of all cannabis users met the criteria for cannabis use disorder. Among people who used cannabis exclusively for medical purposes, 13.4% still qualified for a diagnosis. Even the rate of moderate-to-severe addiction among medical-only users, though lower at 1.3%, confirms that therapeutic use is not risk-free.
These numbers challenge the notion that a doctor’s recommendation somehow insulates patients from dependency. A medication that produces clinically diagnosable addiction in roughly one out of seven medical users would face serious scrutiny in the standard drug approval process.
Cardiovascular Risks From Smoking
Cannabis smoking is independently associated with heart attack risk, even after researchers adjust for tobacco use. A systematic review of 22 studies found that the odds of a heart attack among cannabis smokers ranged from 1.03 to 5.24 times higher than non-users, with particularly elevated risk in younger people. Among people who never smoked tobacco, frequent cannabis smoking still nearly doubled the risk of heart attack, with an adjusted odds ratio of 1.88.
One important nuance: non-smoked forms of cannabis, such as edibles, did not show a statistically significant increase in heart attack risk in most analyses. However, edible cannabis was associated with a higher rate of emergency department visits for cardiovascular symptoms (8.0% versus 3.1% for inhaled forms). And at least one case report documented cardiac damage in a 17-year-old with no prior heart conditions after vaping cannabis. The cardiovascular risks are real, and smoking remains the most common method of use in medical programs.
Traffic Fatalities and Workplace Injuries
Impaired driving is one of the most tangible public safety concerns. Research estimates that traffic fatalities increase by about 2.2 deaths per billion vehicle miles traveled after states begin retail cannabis sales, potentially accounting for around 1,400 additional traffic deaths annually across the country. States that legalized earlier experienced larger increases. The presence of cannabis in fatal crash victims rose from 4.2% in 1999 to 12.2% by 2010 among states with medical marijuana laws.
The picture for medical marijuana specifically is more mixed. Some research found that medical legalization alone did not produce an overall increase in traffic deaths, and certain states even saw an 11% decrease, possibly because some patients substituted cannabis for alcohol. But the broader trend after full legalization, which medical programs often pave the way for, points clearly upward.
Workplace safety follows a similar pattern. A study published in JAMA Health Forum found that recreational legalization was associated with roughly a 10% increase in workplace injuries among workers aged 20 to 34. The estimated injury elasticity suggests that for every percentage-point increase in marijuana use, workplace injuries rise by 0.2 to 0.4 percentage points.
Risks to Children
Accessible cannabis products, particularly edibles that resemble candy or baked goods, have created a sharp increase in pediatric emergencies. Among children aged 10 and under, cannabis-related emergency department visits surged dramatically in recent years. National Poison Data System records show that cases of edible cannabis ingestion among children under 6 increased by 1,375% between 2017 and 2021, with corresponding increases in the severity of those cases.
Medical marijuana programs create a pipeline of cannabis products into homes with children. Unlike prescription medications that come in child-resistant packaging with clear dosing labels, many cannabis edibles are sold in forms that are inherently attractive to young children and carry inconsistent labeling about potency.
The Regulatory Gap
Perhaps the most fundamental argument against medical marijuana is not that cannabis has no therapeutic value, but that the current system of state-level programs is a poor substitute for proper pharmaceutical regulation. Patients receive products of variable potency, inconsistent purity, and unproven efficacy for many of the conditions they’re treating. They face real risks of addiction, cardiovascular harm, and psychiatric effects without the informed consent process that accompanies properly studied medications.
The FDA has approved one cannabis-derived drug and several synthetic versions, demonstrating that cannabis compounds can go through the standard approval process. Critics of medical marijuana argue that this is the path all cannabis-based treatments should take: rigorous testing, standardized dosing, quality-controlled manufacturing, and proper labeling. Anything less holds cannabis to a lower standard than every other medicine on the pharmacy shelf.